What AI says about Zynteglo

ZYNTEGLO is an FDA-approved gene therapy for adult and pediatric patients with beta thalassemia who require regular blood transfusions. In clinical studies, approximately 89% of treated patients achieved transfusion independence with normal or near-normal hemoglobin levels.